Even though the production was stopped, the company will continue to monitor vaccinated volunteers in the C. diff trialand report any findings to the medical community.
This is the latest setback to Sanofi’s vaccine program. On Wednesday the company said use of its new dengue vaccine may be limited after evidence revealed the vaccine could worsen the disease in people who have not been previously exposed to the virus.
More articles on supply chain:
FDA: Biotin supplements may interfere with lab tests
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches ‘real-time benefits’ tool to increase price transparency
